NuvoAir raises $3M to help patients monitor respiratory diseases with AI
With air quality not improving any time soon (hello pollution!), respiratory conditions are on the rise. This has created an opportunity for startups to employ smartphones to monitor respiratory diseases with apps and smart devices.
ResApp’s smartphone app, called ResAppDx, diagnoses a wide range of respiratory illnesses accurately by using cough sounds. Healthymize listens for signals of COPD (chronic obstructive pulmonary disease) when you make calls.
NuvoAir is a new digital therapeutics startup that is also tackling this problem. It has now closed a financing round of $3 million led by venture capital firm Industrifonden, one of the largest life science and tech investors in the Nordics. The round also saw participation from existing investor Investment AB Spiltan.
Aria, NuvoAir’s digital therapeutics software, sends a patient personalized care suggestions based their condition.
NuvoAir aims to make respiratory diseases measurable and more treatable. Established in 2015, NuvoAir launched a smartphone-connected “spirometer,” making real-time lung function assessment possible at home. It has now collected more than 500,000 spirometry tests in the last three years. These tests power its machine learning algorithms to provide insights to patients, their physicians and pharma companies.
Lorenzo Consoli, CEO of NuvoAir, said, “This investment and partnership can significantly advance our focus on digital therapeutics and bring to market new smart devices to help patients manage their condition while improving physicians’ clinical decisions.”